Browsing by Author "Marin, Gustavo H."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Antimicrobial Consumption in Latin American Countries: First Steps of a Long Road Ahead
    (2022) Marin, Gustavo H.; Giangreco, Lucia; Dorati, Cristian; Mordujovich, Perla; Boni, Silvia; Mantilla-Ponte, Hilda; Alfonso Arvez, Ma Jose; Lopez Pena, Monica; Aldunate Gonzalez, Ma Francisca; Fung, Shing Mi Ching; Barcelona, Laura; Campana, Laura; Vaquero Orellana, Alejandra; Orjuela Rodriguez, Tatiana; Gines Cantero, Larissa; Villar, Rosa A.; Sandoval Fuentes, Nicole; Melero, Emiliano; Marin-Piva, Hugo; Soler, Gisela; Gabriel, Fernanda; Pineda Velandia, Laura; Ojeda Florentin, Cinthia; Risso Patron, Soledad; Ortiz Rivas, Mariela; Mendoza Benitez, Carolina; Mellado, Rosemarie; Ivanovska, Verica; Muller, Arno; Rojas, Robin; Castro, Jose Luis
    Background: Irrational antimicrobial consumption (AMC) became one of the main global health problems in recent decades. Objective: In order to understand AMC in Latin-American Region, we performed the present research in 6 countries. Methods: Antimicrobial consumption (J01, A07A, POI AB groups) was registered in Argentina, Chile, Colombia, Costa Rica, Paraguay, and Peru. Source of information, AMC type, DDD (Defined Daily Doses), DID (DDD/1000 inhabitants/day), population were variables explored. Data was analyzed using the Global Antimicrobial Resistance and Use Surveillance System (GLASS) tool. Results: Source of information included data from global, public, and private sectors. Total AMC was highly variable (range 1.91-36.26 DID). Penicillin was the most consumed group in all countries except in Paraguay, while macrolides and lincosamides were ranked second. In terms of type of AMC according to the WHO-AWaRe classification, it was found that for certain groups like "Reserve," there are similarities among all countries. Conclusion and Relevance: This paper shows the progress that 6 Latin-American countries made toward AMC surveillance. The study provides a standardized approach for building a national surveillance system for AMC data analysis. These steps will contribute to the inclusion of Latin-America among the regions of the world that have periodic, regular, and quality data of AMC.
  • No Thumbnail Available
    Item
    Data sources for drug utilization research in Latin American countries-A cross-national study: DASDUR-LATAM study
    (2022) Lopes, Luciane C.; Salas, Maribel; Serpa Osorio-de-Castro, Claudia Garcia; Leal, Lisiane Freitas; Doubova, Svetlana, V; Canas, Martin; Dreser, Anahi; Acosta, Angela; Baldoni, Andre Oliveira; Bergamaschi, Cristiane de Cassia; Mota, Daniel Marques; Gomez-Galicia, Diana L.; Sepulveda-Viveros, Dino; Delgado, Edgard Narvaez; Lima, Elisangela da Costa; Chandia, Felipe Vera; Ferre, Felipe; Marin, Gustavo H.; Olmos, Ismael; Zimmermann, Ivan R.; Fulone, Izabela; Roldan-Saelzer, Juan; Sanchez-Salgado, Juan Carlos; Castro-Pastrana, Lucila, I; Carneiro de Souza, Luiz Jupiter; Beltran, Manuel Machado; Silva, Marcus Tolentino; Mena, Maria Belen; de Franca Fonteles, Marta Maria; Urtasun, Martin A.; Tarapues, Monica; Hernandez, Patricia Granja; Medero, Natalia; Herrera-Comoglio, Raquel; Barberato-Filho, Silvio; Galvao, Tais Freire; Luiza, Vera Lucia; Santa-Ana-Tellez, Yared; Rodriguez-Tanta, Yesenia; Elseviers, Monique
    Purpose Drug utilization research (DUR) contributes to inform policymaking and to strengthen health systems. The availability of data sources is the first step for conducting DUR. However, documents that systematize these data sources in Latin American (LatAm) countries are not known. We compiled the potential data sources for DUR in the LatAm region. Methods A network of DUR experts from nine LatAm countries was assembled and experts conducted: (i) a website search of the government, academic, and private health institutions; (ii) screening of eligible data sources, and (iii) liaising with national experts in pharmacoepidemiology (via an online survey). The data sources were characterized by accessibility, geographic granularity, setting, sector of the data, sources and type of the data. Descriptive analyses were performed. Results We identified 125 data sources for DUR in nine LatAm countries. Thirty-eight (30%) of them were publicly and conveniently available; 89 (71%) were accessible with limitations, and 18 (14%) were not accessible or lacked clear rules for data access. From the 125 data sources, 76 (61%) were from the public sector only; 46 (37%) were from pharmacy records; 43 (34%) came from ambulatory settings and; 85 (68%) gave access to individual patient-level data. Conclusions Although multiple sources for DUR are available in LatAm countries, the accessibility is a major challenge. The procedures for accessing DUR data should be transparent, feasible, affordable, and protocol-driven. This inventory could permit a comparison of drug utilization between countries identifying potential medication-related problems that need further exploration.